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2n February 17, 2009, the President signed into
law the American Recovery and Reinvestment
Act (ARRA). Designed to stimulate the ailing
conomy, the $787 billion legislation included a $10.4
illion allocation to the National Institutes of Health
NIH). These monies were intended to support scientific
esearch priorities ($8.2 billion); extramural construction,
epairs, and alterations ($1 billion); shared instrumentation
nd other capital equipment ($300 million); NIH buildings
nd facilities ($500 million); and comparative effectiveness
esearch ($400 million). The ARRA presented the National
eart, Lung, and Blood Institute (NHLBI) with a number
f unprecedented challenges and opportunities. Now, ap-
roximately 1 year later, we are in a position to offer some
eflections about lessons learned.
ottom-Line Facts and Figures
total of $763 million were allocated to the NHLBI (Fig. 1);
n addition, the Office of the Director of NIH allocated $68
illion of comparative effectiveness research money to projects
hat fall within the mission of the NHLBI. The 2 largest
ategories of spending were for grants to investigators who
esponded to the NIH-wide requests for applications (RFAs),
ncluding challenge grants, grand opportunity (“GO”) grants,
nd small-business awards ($351 million); and grants to 358
nvestigators who had previously submitted investigator-
nitiated research proposals that were highly meritorious but
rom the Division of Cardiovascular Sciences, National Heart, Lung, and Blood
nstitute, Bethesda, Maryland. Dr. Lauer is an employee of the National Heart, Lung,
nd Blood Institute.a
Manuscript received February 10, 2010; revised manuscript received March 24,
010, accepted March 29, 2010.issed the pay-line ($292 million). Additional monies were
pent to support research employment opportunities for young
nvestigators and summer research experiences for students and
ducators. Complete details about NHLBI ARRA spending
an be found on our website (1). The NIH’s “ARRA invest-
ent reports” (2) provide overviews of support for specific
isease areas and research topics, including specific project
xamples. Interested readers can find specific details about all
f the NIH ARRA-funded projects with the “RePORTER”
uery tool (3).
The NHLBI supported 136 challenge grants and 60
GO” grants. The major challenge grants topic areas in-
luded clinical research, biomarkers, enabling technologies,
omparative effectiveness research, genomics, regenerative
edicine, and translational science. The major GO grant
opic areas included large-scale deoxyribonucleic acid se-
uencing and molecular profiling, genomics beyond
enome-wide association studies, comparative effectiveness
esearch, novel methods for assessing health disparities,
esting mechanistic hypotheses, and translation of funda-
ental research findings into clinical treatments.
hallenges
he biggest initial challenge we faced was an extraordinarily
ight timeline. Because the ARRA was an economic stim-
lus bill, it was expected that we would allocate funds within
scal year 2009, which ended on September 30. Compared
ith standard NIH timelines, this left us with little time to
ake high-level strategic decisions, write and release RFAs,
nswer queries from interested investigators, subject appli-
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July 13, 2010:234–6 NHLBI and the American Recovery and Reinvestment Actations to rigorous peer review, make funding decisions,
btain approvals from the NHLBI Advisory Council, and
ork with successful applicants to finalize budgets and
pecific aims.
Our second challenge stemmed from a perception that the
IH was suddenly “in a fishbowl.” The $10.4 billion
llocation received a great deal of media attention (4), and
any in the scientific community and in the public at large
ere understandably skeptical as to whether the NIH could
ise to the opportunity. It was clear to us that we could not
imply continue “business as usual,” but we had to take
dvantage of the sudden influx of money to fund innovative,
cientifically valuable research that would not have been
ossible without the legislation.
Our third challenge was the need to generate mechanisms
o support 2-year projects. The typical NIH grant funds
cientists for 4 to 5 years, with some large projects (like
ivotal clinical trials) lasting even longer. The ARRA
rovided funding for 2 years, requiring us to focus on the
inds of projects that could yield rapidly scientifically
eaningful output.
igure 1 The Recovery Act at the NHLBI
RDG-SPAN  Biomedical Research, Development, and Growth to Spur the Ac
nstitute; NIH  National Institutes of Health; RFA  Request for Application.
as of September 1, 2009) and do not include Recovery Act-specific funds proessons
e believe that 4 factors made it
ossible for us to meet these chal-
enges: a well-developed strategic
lan, a well-informed NHLBI
rogram staff, a flexible adminis-
rative infrastructure, and an en-
aged scientific community.
trategic planning. In 2007,
he NHLBI completed a com-
rehensive Strategic Plan (5), which culminated from 2
ears of work that included hundreds of extramural
cientists and dozens of NHLBI scientific staff. The plan
rovided a detailed blueprint for a comprehensive re-
earch program including basic, translational, clinical,
nd population sciences. On March 9, 2009, senior
HLBI leadership participated in a full-day retreat
esigned to develop a high-level plan for the Institute’s
pproach to the ARRA. We were able to agree upon a
eneral philosophy as well as write RFAs (6) mainly
ecause we had been engaged in strategic planning for
ears.
Abbreviations
and Acronyms
ARRA  American Recovery
and Reinvestment Act
GO  grand opportunities
NHLBI  National Heart,
Lung, and Blood Institute
NIH  National Institutes of
Health
RFA  request for application
tion of New Technologies; NHLBI  National Heart, Lung, and Blood
amounts represent 2009 NHLBI Recovery Act funding plan only
by the NIH Office of the Director.celera
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NHLBI and the American Recovery and Reinvestment Act July 13, 2010:234–6ell-informed staff. Over a period of a few weeks, our
taff wrote and vetted a number challenge- and GO-grant
FAs (6,7). We took advantage of our staff’s expertise in a
ide spectrum of biomedical science, ranging from molec-
lar biology to population epidemiology.
lexible administrative infrastructure. Typical NIH RFAs
ocus on specific topics; for example, the NHLBI recently
eleased an RFA to support work in progenitor cell biology
8) and an RFA to support cardiovascular outcomes research
9). With the ARRA, we had to develop flexible RFAs that
ould simultaneously address applications dealing with
ide-ranging topics. Our success in writing, posting, and
rocessing this new type of RFA was possible because we
lready had well-developed administrative procedures in
lace and we had a cadre of administrative professionals
ithin our division of extramural research activities (also
nown as “DERA”) who could adapt existing administrative
rocedures to the new requirements of the ARRA.
n engaged scientific community. The NIH received
early 22,000 applications in response to the ARRA, clear
vidence that the scientific community was ready and eager
o put forth a high volume of research proposals. After
he NHLBI initially released its challenge- and GO-grant
FAs, our staff received thousands of queries from poten-
ially interested investigators, eager to know whether their
deas might be responsive. Because of the extraordinarily
arge number of applications received, we had the opportu-
ity to assemble a cohesive and comprehensive research
rogram that covers a wide range of cardiovascular biology
nd disease.
ext Steps
ow that the initial phase of the ARRA is over, we are
cutely aware of a number of ongoing and future challenges.
e are keeping particularly close tabs on high-cost, high-
rofile projects, including a multisite project for large-scale
eoxyribonucleic acid sequencing of well-characterized
HLBI cohorts (10) and a pivotal multicenter randomized
rial testing a hypothesis that computed tomography an-
iography is superior to standard stress testing for the
valuation of patients with suspected coronary disease (11).
rrespective of future NIH funding, major failures of large-
cale ARRA projects could jeopardize NIH’s standing.
cross all of the ARRA projects, we will need to apply valid
nd objective metrics to help us understand which programs
ere most successful and why. We plan to capitalize on the
RRA experience by combining these metrics with our
eflections on strategic planning, staff skills and expertise,
dministrative processes, and engagement with the scientific
ommunity.
We expect that over the next few grant cycles, we will see annusually large number of applications, because unsuccessful KRRA applicants will reattempt to secure funding via standard
IH funding mechanisms. Perhaps the biggest challenge, one
hat is acutely in the minds of NHLBI staff and extramural
cientists alike, is the question of what will happen after the
RRA funding concludes. The ARRA represented a 17%
ncrease in the NIH budget for fiscal years 2009 and 2010;
ompared with the baseline (i.e., excluding the ARRA) 2010
udget of $31 billion, the NIH budget for 2011 is only
xpected to increase by 3.2% to a total of $32 billion. Some
ave argued that, for the NIH budget to adequately meet
cientific demands, it must be increased to as much as $37
illion (12). If, as we hope, many of the our funded ARRA
rojects are successful, we would expect that most if not nearly
ll investigators will be competing for continued funding; this
ill present the NHLBI with the need to make progressively
ore difficult decisions about how best to exploit the riches and
essons of the ARRA in the years to come.
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